Revance Therapeutics Inc RTI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RTI is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.76
- Day Range
- $2.68–2.68
- 52-Week Range
- $2.48–33.00
- Bid/Ask
- $2.60 / $2.66
- Market Cap
- $279.92 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.10
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 597
- Website
- https://www.revance.com
Comparables
Valuation
|
Metric
|
RTI
|
PTGX
|
CRNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 13.68 | — |
Price/Book Value | — | 3.49 | 4.07 |
Price/Sales | 1.10 | 6.36 | 1,439.05 |
Price/Cash Flow | — | 10.46 | — |
Price/Earnings
RTI
PTGX
CRNX
Financial Strength
|
Metric
|
RTI
|
PTGX
|
CRNX
|
|---|---|---|---|
Quick Ratio | 4.45 | 15.61 | 17.59 |
Current Ratio | 5.37 | 15.72 | 17.72 |
Interest Coverage | −15.52 | — | — |
Quick Ratio
RTI
PTGX
CRNX
Profitability
|
Metric
|
RTI
|
PTGX
|
CRNX
|
|---|---|---|---|
Return on Assets (Normalized) | −35.34% | 51.28% | −33.04% |
Return on Equity (Normalized) | — | 56.32% | −37.88% |
Return on Invested Capital (Normalized) | −47.94% | 51.24% | −39.10% |
Return on Assets
RTI
PTGX
CRNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Qpshzczj | Wdcwrqx | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pjfxjbywt | Xftrfpb | $114.2 Bil | |||
| Moderna Inc
MRNA
| Sksckdqp | Rrw | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Pysbvqmgv | Csg | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Wmvzvbhyl | Lfx | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xgyzvktmx | Wnvlbj | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rmctcfyx | Lbrcrqc | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Ncdxyhstl | Qrh | $12.8 Bil | |||
| Incyte Corp
INCY
| Ljybrkmnf | Byvlf | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mlbgppxh | Lgjvzf | $12.2 Bil |